High energy costs are behind DSM's decision to temporarily halt production of its animal-grade vitamin A product, Rovimix Vitamin A, which is made in Sisseln, Switzerland. Due to its common upstream infrastructure, the manufacture of Rovimix Vitamin E-50 will also be impacted, said DSM.
“We see this as a temporary measure,” a company spokesperson told DairyReporter. “The shutdown is set for two months [commencing January 2, 2023]. We will continue to carefully monitor energy and raw material costs and will adapt our mid-term supply strategy as required.”
DSM did not comment how stopping production would affect staff at Sisseln but said that it remained ‘committed to its highly skilled and dedicated workforce…and continues to invest heavily in R&D and manufacturing facilities’.
“Over the years, we have invested in our assets in the heart of Europe and have upgraded these to stay competitive and lead in high-quality sustainable vitamin production,” the spokesperson added. “We remain committed in alignment with our aim to generate sustainable profitable growth while at the same time having a positive impact on the world.”
In the meantime, DSM said it is set to honor existing contractual commitments and allocation procedures had been activated across the global production network ‘to enact this in an orderly manner’.